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ABSTRACT 
This document was developed by the Pharmacogenetics (PGx) Working Group of the Association for 
Molecular Pathology (AMP) Clinical Practice Committee, whose aim is to recommend variants for 
inclusion in clinical pharmacogenetic testing panels. The goals of the AMP PGx Working Group are to 
define the key attributes of PGx alleles recommended for clinical testing, and to define a minimum set of 
variants that should be included in clinical PGx genotyping assays. These recommendations include a 
minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid 
clinical laboratories when designing PGx assays. The Working Group considered variant allele 
frequencies in different populations and ethnicities, the availability of reference materials, as well as 
other technical considerations for PGx testing when developing these recommendations. These CYP2C19 
genotyping recommendations are the first of a series of recommendations for PGx testing. These 
recommendations are not to be interpreted as restrictive but to provide a helpful guide.    
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Introduction 
This document describes recommendations from the Association for Molecular Pathology (AMP) 
Pharmacogenomics (PGx) Working Group for a minimum set of alleles to include in clinical cytochrome 
P450 2C19 (CYP2C19) genotyping panels. These recommendations are intended to inform clinical 
laboratory professionals when designing and validating clinical pharmacogenetic (PGx) assays, to 
promote standardization of PGx testing across different laboratories, and to complement other clinical 
guidelines such as those issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC), 
which primarily focuses on the interpretation of genotyping results and therapeutic recommendations 
for specific drug(s).
1
 The specific aims of this Working Group are to define the key attributes of alleles 
that are recommended for clinical PGx testing and to recommend variants for inclusion in clinical 
CYP2C19 testing panels.   
Reasons for Pharmacogenetic Test Standardization  
In the United States, clinical laboratories performing genetic testing must comply with the 
Clinical Laboratory Improvement Amendment (CLIA) standards and guidelines for clinical genetic testing 
(Electronic Code of Federal Regulations Part 493—Laboratory Requirements: Clinical Laboratory 
Improvement Amendments of 1988, https://www.ecfr.gov/cgi-bin/text-
idx?SID=1248e3189da5e5f936e55315402bc38b&node=pt42.5.493&rgn=div5, last accessed 8/25/2017).  
These regulations require clinical laboratories to include the list of interrogated PGx variants and star (*) 
alleles, and assay limitations in their reports; however, there currently are no professional 
recommendations on which variants to include in clinical PGx tests. A recent Genetic Testing Reference 
Material Program (GeT-RM) study utilized a number of PGx test panels, and examination of the assay 
designs revealed that the variants included were not consistent between panels.2 Without exception, no 
two tests that examined any of the 28 PGx genes included in the study were designed to detect the 
same set of variants and/or haplotypes (alleles).2 Similar findings were recently reported by Moyer et al 
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when they surveyed laboratories offering PGx services for CYP2D6 and CYP2C19 genotyping.
3
 In 
addition, some tests used different combinations of variants to define haplotypes and results were 
reported using different nomenclature systems (eg, Human Genome Variant Society,
4
 dbSNP,
5
 star (*) 
alleles).
6
 Variations in test design and nomenclature can impact haplotype and diplotype assignment, 
and ultimately alter test interpretation and patient care. Notably, the AMP has previously supported 
CPIC’s efforts in standardizing PGx allele function and phenotype nomenclature 
(https://www.amp.org/AMP/assets/File/position-
statements/2015/AMPendorsementoftheCPICinitiative2015-10-26.pdf, last accessed 6/23/2017). 
Defining the key attributes of PGx alleles recommended for clinical testing, along with a 
minimum set of variants that should be included in clinical PGx genotyping test panels, as a strategy is 
analogous to the 2001 and 2004 recommendations developed by the American College of Medical 
Genetics and Genomics (ACMG)/American College of Obstetricians and Gynecologists (ACOG) of a panel 
of 25 CFTR pathogenic variants (later revised to 23) for cystic fibrosis carrier (CF) screening in the US
7,8
 
(ACMG, https://www.acmg.net/Pages/ACMG_Activities/stds-2002/cf.htm , accessed 1/30/18). Although 
many clinical laboratories often include other CFTR pathogenic variants in addition to the 23 
recommended pathogenic variants (National Center for Biotechnology Information, 
https://www.ncbi.nlm.nih.gov/gtr/conditions/C0010674/, accessed 1/30/18), adoption of these 
ACMG/ACOG recommendations helped to standardize CF carrier testing in the US and make the 
development and evaluation of assays more transparent.   
Considering the complex nature of clinical PGx testing and interpretation, and its impact on 
patient care, there is a practical need for standardizing clinical PGx assays. Standardized test panels 
developed for clinical PGx assays could also facilitate clinical PGx implementation. Variants and alleles 
for each gene could be selected using criteria such as population frequency, level of supporting evidence 
for phenotypic outcome, clinical utility, and severity of adverse drug reaction or loss of efficacy. Such 
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standardized PGx test panels could enable physicians, pharmacists, researchers, and other stakeholders 
to understand PGx test results without extensive scrutiny of the alleles included in the assay, and 
provide assurance that clinical laboratory panels include a minimum set of clinically relevant PGx variant 
alleles. This is especially important when test results, originally obtained to assist selection and dosing of 
one medication, are used later in the patient’s life for selection and dosing of a different medication. As 
with CFTR testing, laboratories could add additional variants to their panels for expanded clinical PGx 
testing; however, all commercial PGx assays and laboratory-developed tests would theoretically contain 
a consistent minimum set of variants. Evidence-based recommendations developed by professional 
organizations often form the basis for future laboratory accreditation requirements. 
The AMP PGx Working Group cited important issues that are unique to pharmacogenetics which 
need to be considered when developing standardized panels. First, allele function derived from in vitro 
models may not directly translate to a clinical phenotype or metabolizer status (ie, poor metabolizer, 
intermediate metabolizer, normal metabolizer, rapid metabolizer, and ultrarapid metabolizer), and 
allele function can be substrate and/or drug concentration dependent. Although an allele may be 
extremely rare in the general population, it may be more frequent in a specific ethnic population or in a 
phenotypically selected group of patients (eg, those with side effects on specific drugs). Therefore, the 
inclusion of rare, but potentially clinically significant alleles in recommended panels needs to be 
considered. Second, like other PGx genes, variants in CYP2C19 are typically reported as star (*) allele 
inferred haplotypes and diplotypes. A haplotype refers to a set of DNA sequence variants including 
single nucleotide variants (SNVs) or structural variants inherited as a unit on a single chromosome. The 
combination of haplotypes from both chromosomes is generally reported together as a diplotype. The 
diplotype is usually translated into a predicted phenotype or metabolizer status which clinicians use for 
prescribing drugs. For CYP2C19, alleles negative for the assayed sequence variants are designated as *1, 
which is typically the most common or normal function allele. However, the *1 designation may not be 
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accurate if additional, undetected variants are present. The known CYP2C19 star (*) alleles are cataloged 
by the Human Cytochrome P450 (CYP) Allele Nomenclature Committee 
(https://www.pharmvar.org/gene/CYP2C19, last accessed 11/30/2017). CYP2C19 alleles definitions are 
also available through PharmGKB (https://www.pharmgkb.org/gene/PA124#tabview=tab4&subtab=31, 
last accessed 6/20/2017). The list of recommended alleles will require periodic re-evaluation as novel 
variants are identified and characterized, and new insights into genotype-phenotype relationships are 
established. Each new allele will need to be evaluated by the same criteria to assess importance and 
added to the standardized test panel if the criteria are met. In some cases, further research may 
determine that an allele previously on the recommended test panel no longer meets the required 
criteria.    
The availability of reference materials (RMs) was an important consideration for 
recommendation of inclusion of CYP2C19 alleles in clinical genotyping test panels. Well-characterized 
RMs are fundamental to laboratory quality assurance (QA) programs, internal QA activities such as 
quality control (QC), test development/validation,
9
 and periodic external assessment by proficiency 
testing (PT). Selection of appropriate RMs is based on the needs of the assay, test methodology, and 
availability. To meet the need for publicly available, characterized RMs, the Centers for Disease Control 
and Prevention (CDC), in partnership with the clinical testing community, established the GeT-RM 
Program (http://wwwn.cdc.gov/clia/Resources/GetRM/ , last accessed 6/20/2017). Its goal is to improve 
the supply of publicly available and well-characterized genomic DNA that can be used as RM for PT, QC, 
test development/validation, and research studies. In conjunction with AMP, GeT-RM coordinated the 
characterization of 107 DNA samples for clinically relevant polymorphisms for PGx loci, including 
selected CYP2C19 alleles.10 A second study characterized 137 selected DNA samples for 28 PGx genes, 
including CYP2C19.2 These DNA samples are publicly available through the Coriell Cell Repositories 
(Camden, NJ). 
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Although high-throughput DNA sequencing has become more common, many PGx genes are 
difficult to interrogate by commonly used capture-based short-read sequencing platforms due to 
sequence homologies and interference of pseudogenes.
11
  Regardless of the methodology, the AMP PGx 
Working Group believes that establishing recommendations for a minimum set of alleles/variants that 
should be included in clinical PGx test panels is an important step forward to ensure better 
standardization and inter-laboratory concordance of PGx testing. This AMP PGx document on CYP2C19 
allele selection is intended to be the first of a series of PGx gene recommendations for laboratories 
offering clinical PGx testing.   
Goals of Recommendations 
As noted above, the goals of the AMP PGx Working Group are to define the key attributes of 
PGx alleles recommended for clinical testing, and to define a minimum set of variants that should be 
included in clinical PGx genotyping assays. These recommendations include a minimum panel of variant 
alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when 
designing PGx assays. When developing these recommendations, the Working Group considered variant 
allele frequencies in different populations and ethnicities, the availability of RMs, as well as other 
technical considerations for PGx testing. The aim is that these recommendations will facilitate more 
consistent PGx testing across clinical laboratories.  
Gene: CYP2C19 
CYP2C19, a member of the cytochrome P450 superfamily, is involved in the phase I metabolism 
of many commonly prescribed medications, including the antiplatelet agent clopidogrel, proton-pump 
inhibitors, and the selective serotonin reuptake inhibitors (SSRIs) antidepressants 
citalopram/escitalopram.12,13 The CYP2C19 gene is located on chromosome 10q23.33 and is highly 
polymorphic, which can lead to large inter-individual variation in CYP2C19 enzyme activity and related 
drug response phenotypes and/or undesired adverse drug events.14 CYP2C19 is one of the most 
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frequently tested PGx genes in clinical laboratories and is included in the Food and Drug Administration 
(FDA) Table of Pharmacogenetic Biomarkers in Drug Labeling for several FDA-approved drugs 
(https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm, last accessed 1/30/2018). 
According to The Genetic Testing Registry 
(https://www.ncbi.nlm.nih.gov/gtr/all/?term=CYP2C19, last accessed 2/12/2017), the CYP2C19 variants 
tested in US clinical laboratories range from a few targeted alleles to the entire coding region. The 
genetic tests utilize a variety of methods including targeted variant detection, bidirectional Sanger DNA 
sequencing, and next-generation sequencing. Factors that lead to inconsistent clinical CYP2C19 testing 
between laboratories includes the choice of tested alleles, targeted testing of populations with varying 
ethnic backgrounds, as well as technical performance of the various platforms. For example, 
laboratories that service a particular ethnic population based on geography may test only for variants 
that are specific to that particular population.    
 
Existing Guidelines 
Clinical PGx practice guidelines are available from additional professional organizations, 
including CPIC (https://cpicpgx.org/guidelines/, last accessed 1/30/2018), the Dutch Pharmacogenetics 
Working Group (DPWG)
15
, and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) 
(http://cpnds.ubc.ca/about/projects, last accessed 6/20/2017). These guidelines, which were developed 
using an extensive literature review and discussion among consortium of individual volunteers who have 
experience or have published on the specific drug or gene, are gene-drug pair oriented with an emphasis 
on interpretation of genotype and phenotype, and genotype-guided therapeutic recommendations. 
These drug-oriented guidelines have played a critical role in facilitating the clinical implementation of 
PGx and have enabled the development of clinical decision support tools for clinicians to understand 
and more efficiently utilize PGx testing results. There are currently 21 dosing recommendations available 
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on CYP2C19-metabolized medications from the CPIC and DPWG (PharmGKB,
16
 
https://www.pharmgkb.org/gene/PA124, last accessed 6/20/2017). Although all guidelines include lists 
of common CYP2C19 alleles reported to date in various populations and their functional and clinical 
relevance, they do not explicitly recommend specific variant alleles for clinical laboratories to include in 
their CYP2C19 testing platforms. Despite the fact that many commercial platforms are available, clinical 
laboratories often develop their own assays for CYP2C19 testing. Specific considerations from a clinical 
laboratory perspective such as CYP2C19 allelic variant selection, testing platforms, and RMs are not 
addressed in the CPIC or DPWG practice guidelines.  
 
CYP2C19 Alleles Recommendation 
The AMP PGx Working Group reviewed the variant CYP2C19 star (*) alleles currently cataloged 
by the CYP450 Allele Nomenclature Committee, including allele function status, multiethnic allele 
frequencies, the availability of RMs, and commercially available genotyping platforms (Table 1). Tier 1 
CYP2C19 variant alleles were defined as those that have: i) well-characterized alteration of CYP2C19 
activity that has been shown to have an effect on drug response and for which the functional variant is 
known, ii) appreciable minor allele frequency in a patient population, and iii) available RMs (Table 2).
2
 
Tier 2 variant CYP2C19 alleles are defined as alleles that meet at least one but not all of the criteria for 
inclusion in Tier 1, and are considered optional for inclusion in expanded clinical genotyping panels. 
These include normal function variant alleles, low frequency alleles, and alleles without currently 
available RMs. Some of the Tier 2 alleles may become Tier 1 in the future if RMs or additional 
information becomes available. Variants with unknown or uncertain function are not recommended for 
inclusion in targeted clinical CYP2C19 genotyping test panels, although it may be useful to include these 
in research panels to clarify functional and clinical outcomes.   
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Tier 1 CYP2C19 Variant Alleles 
CYP2C19 variant alleles considered as Tier 1 by the AMP PGx Working Group include *2, *3, and 
*17. This was based on their well-established functional effect on CYP2C19 activity and drug response,
17
 
availability of RMs, and their frequencies in major ethnic groups.  The major no function CYP2C19*2 
allele is characterized by the presence of a synonymous transition in exon 5 that results in abnormal 
splicing (NM_000769.2:c.681G>A; p.Pro227Pro; rs4244285).
18
 CYP2C19*2 has a minor allele frequency 
ranging from 13% to 54% in most major racial and ethnic groups, and consequently is the most common 
CYP2C19 allele interrogated by clinical laboratories. The no function CYP2C19*3 allele is a 
nonsynonymous transition in exon 4 that results in a premature stop codon (NM_000769.2:c.636G>A; 
p.Trp212Ter; rs4986893).
19
 Although it has a low minor allele frequency (<1%) in most major racial and 
ethnic groups, it has a frequency of ~8% to 10% in the East Asian population. The increased function 
CYP2C19*17 allele is characterized by a promoter variant that results in increased gene expression 
(NM_000769.2:c.-806C>T; rs12248560).
20
 Importantly, the inclusion of these three variants accounts for 
43% to 100% of the currently defined variant CYP2C19 alleles in most major racial and ethnic groups  
(Table 3).
17,21
 In terms of the clinical impact of the recommended Tier 1 recommended alleles, patients 
with CYP2C19 *1/*17 and *17/*17 (rapid and ultra-rapid metabolizer) diplotypes are more likely to have 
lower than desired therapeutic levels of some medications such as voriconazole,
17
 sertraline,
22
 and 
citalopram,
22
 whereas patients with CYP2C19 *2/*2, *2/*3, or*3/*3 (poor metabolizer) diplotypes are 
more likely to have higher than normal levels of these medications with an increased risk for adverse 
events.  Conversely, for the anti-platelet therapy clopidogrel, a prodrug which requires bioactivation by 
CYP2C19, ultra-rapid metabolizers have higher plasma concentrations of the active metabolite, whereas 
poor metabolizers have reduced plasma concentrations of the active metabolite and reduced efficacy of 
anti-platelet inhibition.23  
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Tier 2 CYP2C19 Variant Alleles 
The following CYP2C19 alleles were recommended as Tier 2:  *4A, *4B, *5, *6, *7, *8, *9, *10, 
*35 (Table 4).
17
 These alleles have been shown to have decreased or no function 
(https://www.pharmgkb.org/page/cyp2c19RefMaterials, last accessed 1/30/2018). Moreover, the Tier 2 
alleles have a combined frequency higher than 1% in several major ethnic groups, with the highest 
combined frequency (13%) being observed in populations of African descent
17
. The most common Tier 2 
allele is the *35 allele (NM_000769.2:c.332-23A>G; rs12769205) which is found at 9% frequency in 
Africans. Although these alleles are included in many platforms, they were not included in the Tier 1 
recommendations due to either low minor allele frequency (which can result in an increase of false 
positive results), less well-characterized impact on CYP2C19 function, or a lack of RMs. Specifically, the 
*4A, *4B, *5, *6, *7, and *8 alleles have frequencies less than 0.5% in major ethnic groups; *9 and *10 
are decreased function alleles and, therefore, their clinical significance is uncertain 
(https://www.pharmgkb.org/page/cyp2c19RefMaterials, last accessed 7/26/2017); and RMs are not 
available for *5, *7, *35. Given that *35 was only recently characterized
21
, it was not interrogated in the 
recent CDC GeT-RM study and thus there is no known RM available; nor is it included among the 
majority of currently available commercial platforms (Table 1). As further information is gained about 
*35 and RM becomes available, it may be promoted to a Tier 1 allele.   
Of note, the defining variant of the no function CYP2C19*4 allele (NM_000769.2:c.1A>G; 
rs28399504) can be in linkage equilibrium with the defining variant of CYP2C19*17 (NM_000769.2:c.-
806C>T; rs12248560) in certain ethnic subpopulations and this haplotype has been designated 
CYP2C19*4B. Therefore, to distinguish between the no-function CYP2C19*4B and the increased function 
CYP2C19*17, both defining variants (rs28399504 and rs12248560) need to be interrogated, and 
preferably by a method that can determine their phase.24,25 Additionally, a rare nonsynonymous 
CYP2C19 variant (NM_000769.2:c.463G>T; p.Glu155Ter; rs374036992) also can occur in linkage 
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disequilibrium with the defining variant of CYP2C19*17 (NM_000769.2:c.-806C>T; rs12248560) and this 
haplotype has yet to be assigned an independent star (*) allele designation by the CYP Allele 
Nomenclature Committee. Although it could be useful to interrogate this rare variant and distinguish 
CYP2C19*17 from this novel haplotype, the absence of an independent star (*) allele designation, its low 
frequency, lack of available RM, and its unclear clinical importance limits its inclusion in clinical CYP2C19 
testing panels.
26
  
 
DISCUSSION 
It is important for molecular diagnostic laboratories to have resources to guide them in their 
efforts to offer adequate PGx testing. AMP believes that it is the responsibility of professional 
organizations to establish guidelines for professional practice. Our members are among the early 
adopters and users of PGx testing in clinical settings, and have accumulated substantial knowledge and 
expertise as it relates to this area of clinical testing. This document offers a two-tier categorization of 
CYP2C19 alleles as an aid for designing CYP2C19 genotyping assays. 
Using criteria such as allele function, population frequency, and availability of RMs, the AMP 
PGx Working Group has proposed a recommended minimum set of alleles and their defining variants 
(Tier 1) that should be included in clinical CYP2C19 PGx tests. In addition, we have defined a list of 
CYP2C19 alleles that do not currently meet one or more of the criteria for inclusion in Tier 1 and are thus 
considered optional for clinical testing (Tier 2). These recommendations are intended to facilitate testing 
by laboratories and to improve genotyping concordance across laboratories.    
There are currently four CPIC guidelines for CYP2C19 covering 10 medications: SSRIs;
22
 tricyclic 
antidepressants (TCAs);27 clopidogrel;23 and voriconazole.17 One guideline issued by the DPWG offers 
recommendations for four additional proton pump inhibitors.15  Moreover, within the FDA prescribing 
label, actionable CYP2C19 genotype information is available to physicians for five additional drugs: 
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carisoprodol (Soma Prescribing Label 02/01/2013,  
www.accessdata.fda.gov/drugsatfda_docs/label/2013/011792s045lbl.pdf; last accessed 07/11/ 2017), 
clobazam (Onfi Prescribing Label 12/16/2016,  
www.accessdata.fda.gov/drugsatfda_docs/label/2016/202067s004lbl.pdf; last accessed 07/11/ 2017), 
diazepam (Diastat Prescribing Label 12/16/2016, 
www.accessdata.fda.gov/drugsatfda_docs/label/2016/020648s014lbl.pdf; last accessed 07/11/ 2017) 
brivaracetam (Briviact Prescribing Label 06/03/2016, 
www.accessdata.fda.gov/drugsatfda_docs/label/2016/205836s001,205837s001,205838s001lbl.pdf; last 
accessed 07/11/ 2017), flibanserin (Addyi Prescribing Label 08/18/2015, 
www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf; last accessed 07/11/ 2017). 
Consequently, CYP2C19 PGx testing has the potential to guide clinicians when considering the use of at 
least 15 different medications some of which are amongst the top 200 most prescribed medications in 
the US (http://clincalc.com/DrugStats/, last accessed 11/30/2017). 
Tier 2 CYP2C19 alleles are additional variant alleles that could be included in clinical assays. 
These alleles either have low minor allele frequencies, lack available RMs, or have limited documented 
effects on CYP2C19 function. This represents an opportunity for laboratories to refine their PGX test and 
expand its coverage by including additional Tier 2 alleles. For example, given the frequency of the no 
function CYP2C19*35 allele in African populations, inclusion of this allele may more accurately assign a 
diplotype and a subsequent phenotype for this ethnic group.  
These recommendations for CYP2C19 genotyping do not evaluate the evidence for clinical 
significance or utility, nor do they include information on CYP2C19 genotype interpretation or reporting, 
as these were considered to be out of scope for this document and/or available from other sources (eg, 
PharmGKB, CPIC). However, clinical laboratories that offer CYP2C19 genotyping should be aware that 
different CYP2C19 variant alleles may have distinct clinical implications based on their functional status 
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and can be medication-specific. For example, the no function CYP2C19 alleles (eg, *2 and *3), which can 
result in the CYP2C19 poor metabolizer phenotype, are more relevant to clopidogrel responsiveness 
testing,
23
 whereas the increased function CYP2C19*17 allele, which can result in the CYP2C19 rapid and 
ultra-rapid metabolizer phenotypes, is more relevant to dosing voriconazole
17
 and the SSRIs.
22
  
Pharmacogenetics is a rapidly changing field; therefore, this document is limited to an 
evaluation of the current knowledge base. The AMP PGx Working Group intends to update this 
recommendation document as new evidence and/or RMs become available. The evidence available in 
the existing literature also informed the recommended list of 16 Tier 2 alleles. We anticipate that some 
of these alleles could be updated to Tier 1 alleles as RMs become available and/or as new frequency 
information for specific ethnicities is identified. We recognize that other known CYP2C19 alleles are not 
listed in this recommendation as there are over 35 CYP2C19 alleles listed in the CYP allele nomenclature 
database [https://www.pharmvar.org/gene/CYP2C19, last accessed 1/30/2018)]. Some of these could 
be updated to Tier 2 or even Tier 1 alleles based on new data concerning function, clinical relevance, 
frequency, and future availability of RMs.   
Implementation of this recommendation document is at the discretion of the laboratory. The 
Tier 1 alleles are currently included in the available PT programs (eg, College of American Pathologists 
North American Specialized Coagulation Laboratory Association). The majority of laboratories 
participating in these PT programs currently test for all of the Tier 1 alleles.
28
  This indicates that many 
clinical laboratories are already testing the Tier 1 alleles and that these recommendations would be 
practical to implement and reinforce standardization between laboratories.    
This document is limited to recommendations of alleles to include in clinical laboratory assays 
and does not include information about CYP2C19 genotype-to-phenotype relationship or clinical 
interpretation for CYP2C19 results such as changes to medication therapy. Correlation of genotypes to 
CYP2C19 phenotype expressed as a metabolizer status and recommendations for clinical actions based 
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on CYP2C19 genotypes are included in the clinical practice guidelines published by CPIC, DPWG, and 
other professional societies and regulatory bodies.   
 
DISCLAIMER 
The AMP Clinical Practice Guidelines and Reports are developed to be of assistance to laboratory and 
other healthcare professionals by providing guidance and recommendations for particular areas of 
practice. The Guidelines or Report should not be considered inclusive of all proper approaches or 
methods, or exclusive of others. The Guidelines or Report cannot guarantee any specific outcome, nor 
do they establish a standard of care. The Guidelines or Report are not intended to dictate the treatment 
of a particular patient. Treatment decisions must be made based on the independent judgment of 
healthcare providers and each patient’s individual circumstances. AMP makes no warranty, express or 
implied, regarding the Guidelines or Report and specifically excludes any warranties of merchantability 
and fitness for a particular use or purpose. AMP shall not be liable for direct, indirect, special, incidental, 
or consequential damages related to the use of the information contained herein. 
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Table 1.  Commercial assays currently available for CYP2C19 genotyping. 
Platform 
*
2
 
*
2
A
 
*
2
B
 
*
3
 
*
4
 
*
4
A
 
*
4
B
 
*
5
 
*
5
A
 
*
5
B
 
*
6
 
*
7
 
*
8
 
*
9
 
*
1
0
 
*
1
2
 
*
1
3
 
*
1
4
 
*
1
5
 
*
1
7
 
*
3
5
 
Regulatory 
status† 
Affymetrix 
Pharmacoscan 
  X X X X     X     X X X X X X X X X X   RUO 
Agena 
Biosciences 
(Sequenom) 
iPLEX ADME 
X     X X       X X X X X X   X       X   RUO 
Autogenomics 
INFINITI 
X     X                               X   FDA-cleared 
GenMark 
eSensor  
X     X X     X     X X X X X   X     X   RUO 
Luminex xTAG 
v3 
X     X                               X   FDA-cleared 
LifeTech 
Taqman Open 
Array 
V                                         LDP 
Spartan 
Bioscience 
X     X                               X   FDA-cleared 
Not a comprehensive list. Inclusion herein does not represent an endorsement of any product or service by AMP.  
†Regulatory status of commercially available pla^orms as of 8/31/17. 
FDA, Food and Drug Administration; LDP, laboratory developed procedure; RUO, research use only; X, included; V, variable.  
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Table 2. Currently available Reference Materials for CYP2C19. 
*allele Coriell# 
*2 NA17641(*2/*17) 
NA17673(*1/*2) 
NA20509 (*2/*2) 
NA18484 (*1 (*27)/*2) 
NA18564 (*2/*3) 
NA24009 (*2/*9) 
NA23874 (*2/*6) 
NA07439 (*2/*10) 
NA19122 (*1 (*15)/*2) 
*3 NA18564 (*2/*3) 
NA23246 (*3/*17) 
*4 NA18552 (*1/*4) 
*4B NA23878 (*1/*4B) 
*5 none 
*6 NA19178 (*1 (*27)/*6) 
NA23874 (*2/*6) 
*7 none 
*8 NA07029 (*8/*17) 
NA238739 (*1/*8) 
*9 NA24009 (*2/*9) 
NA24008 (*9/*17) 
*10 NA07439 (*2/*10) 
*12 NA17074 (*1 (*12)/*17) 
*13 NA19239 (*13/*17) 
NA17448 (*1/*13) 
*15 NA19143 (*1/*15) 
NA19122 (*1 (*15)/*2) 
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*17 NA17641(*2/*17), 
NA12236(*1/*17),  
NA17074 (*1 (*12)/*17) 
NA19109 (*17/*17) 
NA19239 (*13/*17) 
NA07029 (*8/*17) 
NA24008 (*9/*17) 
NA23246 (*3/*17) 
*27 NA19178 (*1 (*27)/*6) 
NA18484 (*1 (*27)/*2) 
*35 none  
 
This is not a comprehensive list. Inclusion herein does not represent an endorsement of any product or service by AMP. For a 
complete list, see CDC website. (https://wwwn.cdc.gov/clia/Resources/GETRM/default.aspx, last accessed 
6/20/2017)).
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Table 3.  CYP2C19 Tier 1 variant alleles. 
Allele Allele 
Functional 
Status† 
Defining 
Functional 
Variant 
HGVS 
Nomenclature: 
NM_000769.2 
 HGVS 
Nomenclature: 
NG_008384.2‡ 
Reference 
Material Available 
Multiethnic Allele 
Frequency 
*2§ No function rs4244285 c.681G>A  g.24154G>A Yes 12-54% 
*3 No function rs4986893 c.636G>A  g.22948G>A Yes 0.3-15% 
*17 Increased 
function 
rs12248560 c.-806C>T  g.4195C>T Yes 4-21% 
 † Citations for assignment of function can be found at https://www.pharmgkb.org/page/cyp2c19RefMaterials, , 
last accessed 6/20/2017. 
‡ CYP2C19 RefSeqGene. 
§Note that the defining *2 variant (rs4244285) is most likely linked with the defining variant of the *35 allele (rs12769205); 
however, the *35 definition includes rs12769205 without rs4244285.
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Table 4.  CYP2C19 Tier 2 variant alleles. 
Allele Allele 
Functional 
Status 
Defining Variant(s) HGVS 
Nomenclature: 
NM_000769.2 
HGVS Nomenclature: 
NG_008384.2† 
Reference 
Material 
Available 
Multiethnic 
Allele 
Frequency‡ 
*4A No function rs28399504 c.1A>G g.5001A>G Yes 0.1-0.3% 
*4B No function rs28399504; 
rs12248560 
c.[-806C>T; 1A>G] g.[4195C>T;5001A>G] Yes 0-0.2%
*5 No function rs56337013 c.1297C>T g.95033C>T No 0% 
*6 No function rs72552267 c.395G>A g.17748G>A Yes 0-0.1%
*7 No function rs72558186 c.819+2T>A g.24294T>A No 0% 
*8 No function rs41291556 c.358T>C g.17711T>C Yes 0.1-0.3% 
*9 Decreased 
function 
rs17884712 c.431G>A g.17784G>A Yes 0.1-4.2% 
*10 Decreased 
function 
rs6413438 c.680C>T g.24153C>T Yes 0.1-6% 
*35§ No function rs12769205 c.332-23A>G g.17662A>G No 0.8-3.1% 
†CYP2C19 RefSeqGene; forward relative to chromosome). 
‡From https://www.pharmvar.org/gene/CYP2C19, last accessed 6/20/2017/. 
§Note that the defining *2 variant (rs4244285) is most likely linked with the defining variant of the *35 allele (rs12769205);
however, the *35 definition includes rs12769205 without rs4244285.
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